Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024312 (lymphopenia)
 4,859 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The peripheral blood lymphocyte count has been measured in 74 cases of histologically proven carcinoma of the gastrointestinal tract. The count has been correlated with the pathological stage of tumour spread and the patient's delayed hypersensitivity response to 2.4 dinitrochlorobenzene (DNCB). A statistically significant correlation was found between the peripheral blood lymphocyte count and the response to DNCB. There was linear association between the extent of spread of the tumours and the lymphocyte count. Those patients with low peripheral blood lymphocyte counts tended to have more advanced tumours and a poor response to DNCB. The possible causes of this lymphopenia are discussed.
Br J Cancer 1974 Sep
PMID:Cellular immunity, peripheral blood lymphocyte count and pathological staging of tumours in the gastrointestinal tract. 445 26

Acquired immunodeficiency syndrome (AIDS) is a disease of unknown aetiology characterised by opportunistic infections, unusual malignancies, and aberrations in cellular immunity; lymphopenia and reversal of helper/suppressor T-cell ratios are the most common. In this study the immune function in 25 children and adolescents with haemophilia was assessed. Normal humoral immunity was observed in all patients evaluated. T and B cell numbers and stimulation were within normal limits. However, 5 of the patients had reversed helper/suppressor T-cell ratios similar to, but less pronounced than, the reversed ratio observed in patients with clinical signs of AIDS. These results suggest that patients with haemophilia may be at increased risk of AIDS and that regular investigation of cellular immunity is warranted in these patients.
 ...
PMID:Altered distribution of T-lymphocyte subpopulations in children and adolescents with haemophilia. 613 Dec 13

Fluorescence polarization measurement during the progress of fluorochromasia has been used to study the response of human lymphocytes to phytohaemagglutinin (PHA) and to tumour-associated antigens, as a basis for the detection of malignant disease. Polarization (P) values of both stimulated and unstimulated lymphocytes decreased with increasing intracellular fluorescence intensity, and with the duration of the fluorochromatic reaction. When these effects were taken into account, there was no significant difference in the change of P following stimulation of lymphocytes from 50 cancer patients or healthy subjects; the magnitude of the response was related more to the age of the donor and to the extent of granulocyte contamination of the lymphocyte preparation than to the presence of cancer. There were, however, significant differences in the change in leakage of fluorescein out of the lymphocytes and in the change in hydrolysis rate after PHA stimulation between lymphocytes from healthy individuals and from patients with cancer.
Br J Cancer 1980 Jan
PMID:Response of human lymphocytes to PHA and tumour-associated antigens as detected by fluorescence polarization. 615

A child with Fanconi's anaemia diagnosed at 7 years of age presented in adult life with lymphopenia, recurrent warts and Bowen's disease. The latter resulted in the development of multiple cutaneous squamous cell carcinomas which metastasized to the skeleton. Investigation of her immune function revealed selective defects in natural killer (NK) cell activity. Humoral immunity and several tests of cell-mediated responses were within normal or became normal after treatment with levamisole or transfer factor. Analysis of the defect in NK activity revealed that low levels could be induced in vitro by fibroblast interferon. Stimulation of blood lymphocytes from the patient with the interferon inducer poly (I)-poly (C) resulted in an increase in NK activity but incubation of her lymphocytes on tumour cells did not result in an increase in NK activity or the release of interferon. This contrasted with the marked increase in NK activity and interferon release observed when lymphocytes from normal controls were incubated on tumor cells. These findings suggested the absence of NK activity in this patient was secondary to a defect in interferon release from lymphocytes on exposure to tumour antigens. It is considered that these defects may have been an important predisposing factor in the development of malignancy in this patient and possibly other patients with Fanconi's anaemia.
 ...
PMID:Deficient natural killer cell activity in a patient with Fanconi's anaemia and squamous cell carcinoma. Association with defect in interferon release. 617 61

The effects of recombinant DNA-produced leukocyte interferon (IFLrA) were studied in 37 patients with metastatic cancer who received sequentially escalating doses of 9-86 million units (MU) of IFLrA by im injection twice weekly. The IFLrA was absorbed rapidly and reached a peak serum concentration 6-8 hours after injection. Serum concentration of IFLrA increased proportionately with the dose. The most common side effects included fever, chills, asthenia, anorexia, and weight loss, and leukopenia, granulocytopenia, and lymphopenia occurred frequently. Elevation of serum glutamic-oxaloacetic transaminase was frequent above doses of 50 MU. All side effects were reversible by discontinuation of the drug. Antibodies to IFLrA were detected in 3 patients while on treatment. The presence of antibodies coincided with drastic reduction in serum IFLrA concentration and, in 1 patient, with relapse of disease. Objective tumor responses were documented in patients with lymphomas but not in other groups of patients.
J Natl Cancer Inst 1983 Jun
PMID:Clinical study of recombinant DNA-produced leukocyte interferon (clone A) in a intermittent schedule in cancer patients. 619 33

9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887) is a new purine antimetabolite that has been evaluated in a Phase I clinical trial. The schedule of administration consisted of a single i.v. infusion over a period of 30 min once each day for 5 consecutive days, repeated at 4-week intervals. Thirteen patients received 30 courses of the drug in a dose range of 18 to 40 mg/sq m/day. Granulocytopenia and thrombocytopenia were dose limiting. Repeated courses produced similar degrees of granulocytopenia, but in 7 of 7 patients receiving 2 or more courses, the degree of thrombocytopenia was less severe during the first than during subsequent courses. Myelosuppression in humans was more severe than predicted from the mouse model. Lymphopenia was profound at all dose levels, but reversed within 3 weeks. Somnolence occurred during infusion in 8 of 13 patients, but quickly cleared after the infusion was completed. The infused drug was rapidly dephosphorylated in plasma and then cleared so there was no cumulation of drug in plasma when it was rapidly infused once each day in these doses. Phase II studies of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate are planned at a starting dose of 18 mg/ sq m/day for patients with prior chemotherapy or radiotherapy and 25 mg/sq m/day for those without prior therapy, as a single dose on each of 5 consecutive days repeated at 21- to 28-day intervals.
Cancer Res 1984 Sep
PMID:Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite. 620 52

9-beta-D-Arabinofuranosyl-2-fluoroadenine-5'-monophosphate (NSC 312887) (2-F-ara-AMP) is a new purine antimetabolite with documented preclinical activity against a number of animal tumors. Data from in vitro studies and preclinical animal toxicology trials indicated that 2-F-ara-AMP might be lymphocytotoxic. We studied effects of 2-F-ara-AMP on peripheral lymphocytes of patients receiving the agent in a Phase I clinical trial. Eleven patients received 13 courses given by i.v. bolus daily for 5 days. Mononuclear cells were isolated, and lymphocyte subsets were quantitated by immunofluorescence and flow cytometry 1 day before treatment and 4 hr after the final infusion. Lymphocytopenia developed rapidly (median time to nadir, 6 days) and was reversible. Standard leukocyte counts, differential counts, and percentages of isolated mononuclear cells reactive with monoclonal antibodies were used to calculate numbers of peripheral cells in each major lymphocyte subpopulation. Total T-lymphocyte counts fell during all treatment courses, with calculated mean absolute T-cell counts decreasing by 90%. Decreases were observed in all major T-lymphocyte subsets. By contrast, calculated B-lymphocyte counts decreased an average of 50% and were noted to increase during two treatment cycles. We also compared in vitro recoveries of cells from each major lymphocyte subpopulation before and after administration of 2-F-ara-AMP. Recoveries of total mononuclear cells, total T-cells, and non-T-, non-B-cells all were reduced substantially by 2-F-ara-AMP, but B-cell recovery was not reduced. These in vivo data, the first in human subjects, are in agreement with in vitro studies of halopurine nucleotide analogues which have demonstrated that T-cells are more sensitive than are B-cells to the cytotoxic effects of these compounds.
Cancer Res 1984 Oct
PMID:Effects on human peripheral lymphocytes of in vivo administration of 9-beta-D-arabinofuranosyl-2-fluoroadenine-5'-monophosphate (NSC 312887), a new purine antimetabolite. 620 51

In a model for multiple laparoscopies proliferation of T-lymphocytes was an early, but transitory, immunologic reaction in the spleen to intraperitoneal CO2 insufflation. Intraperitoneal insufflations of approximately 3.5 ml of CO2 were given daily to three groups of BALB/c mice for 11, 20, and 32 consecutive days, respectively. Air insufflation was given to experimental controls. The observations in the insufflation model are summarized as follows: 1) Multiple CO2 insufflation approximately doubled the number of splenic T lymphocytes. 2) The percentage value was highest on the day of the last insufflation. The difference between this value in each of the three groups was statistically not significant; ie, there was no dose-response relationship in the range of 11-32 insufflations. 3) There was a dose-response effect in the range of 3-9 insufflations. 4) The number of splenic T lymphocytes decreased with each day after the end of treatment. Untreated control values were reached in 12-16 days. 5) Air insufflation had only a minimal effect on the proliferation of T lymphocytes in the spleen. In this model there is correlation between early proliferation of T lymphocytes in the spleen and the late occurrence of a high incidence of malignant lymphoma (approximately 60%). The long-term survivors of CO2 insufflation also developed a wide spectrum of intraabdominal malignancies. It was speculated that CO2 insufflation provided an abnormal internal environment that affected a variety of target tissues. Prolonged CO2 accumulation might have modified nucleic acid structure via chronic intracellular acidosis. Could the neoplastic sequelae in this model be a clue to a similar sequel in humans after multiple laparoscopies?
Cancer Detect Prev 1981
PMID:A murine model for multiple laparoscopies: I. Early lymphoid response to intraperitoneal insufflation of CO2. 621 40

The distribution of T-lymphocyte subsets in patients with Hodgkin's disease (HD) at diagnosis and in those disease-free off-therapy for over 5 years, was assessed with OKT monoclonal antibodies. In patients at diagnosis, T-cell subsets appeared substantially balanced with only a moderate reduction in the proportion and absolute number of OKT4 (helper/inducer) positive cells, suggesting that the lymphopenia, constantly associated with HD at diagnosis, is mainly due to a reduction in the helper/inducer T-cell subpopulation. In patients off-therapy, a reduced proportion, but normal absolute number, of OKT4+ cells was constantly accompanied by a significant increase in the proportion and absolute number of OKT8+ cells, compared with patients at diagnosis and normal controls (40% +/- 11 versus 24% +/- 7 and versus 23 +/- 6, respectively). Consequently the OKT4/OKT8 ratio, normal or near normal in patients at diagnosis (1.70 versus 2.00), was significantly reduced in patients off-therapy (0.78 versus 2.00, P less than 0.001). These data suggest that in patients with HD at diagnosis, T-cell subpopulations are substantially normal, while a significant abnormality was observed in patients with HD off-therapy and potentially "cured." Further investigations will better elucidate these findings probably related to the cytotoxic radiotherapy and chemotherapy.
Cancer 1983 Oct 15
PMID:Increased proportion of suppressor/cytotoxic (OKT8+) cells in patients with Hodgkin's disease in long-lasting remission. 622 7

Using direct imunofluorescence, lesions from 266 human breast specimens were studied for the presence of IgA, IgM, or IgG localization. The lesions included benign elements from 66 subcutaneous mastectomy specimens in which the absence of simultaneous breast malignancy was documented, primary breast carcinomas from 153 mastectomy specimens, and 47 biopsies containing metastatic breast cancer. A statistically significant association of IgA and IgM with benign lesions was contrasted to the association of IgG with malignant lesions. In both primary and metastatic lesions, IgG localization was associated with estrogen-receptor-poor primary cancers as compared with estrogen-receptor-rich primary cancers. Among primary breast cancer patients, IgG localization in the tumor correlated with relative lymphopenia. A shorter disease-free interval was noted in association with IgG localization among the metastatic breast lesions. No statistically significant association between stage of disease and immunoglobulin presence was demonstrable. Moderate-to-severe intraductal epithelial hyperplasias were more often associated with immunoglobulin G localization that were other benign lesions.
Cancer 1981 Jul 01
PMID:Immunoglobulin localization in benign and malignant lesions of the human mammary gland. 626 53


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>